Patrick Weiss joined ARCH as a Venture Partner in 2022. In this capacity Patrick is focused on identifying and evaluating new breakthrough life science technologies. He also assists in creating, scaling and operating ARCH portfolio companies.
Patrick joins ARCH from Twist Bioscience, a company providing synthetic DNA-based products based on a disruptive and proprietary technology, including synthetic genes, tools for NGS sample preparation, and antibody libraries for drug discovery and development. During his tenure as COO, he played a pivotal role in navigating Twist from a small pre–Series A start-up to a successful publicly traded company. Prior to Twist he was the CEO of Operon Biotechnologies, a global leader in nucleic acid synthesis, sequencing and bio-informatics services, Vice President Gene silencing at Qiagen responsible for its RNA synthesis and siRNA product portfolio and Founder and CEO of Xeragon Inc., a global leader in RNA synthesis and related products.
He currently serves on the board of Slingshot Biosciences and Scale Biosciences.
Patrick holds a MSc ETH from the Swiss Federal Institute of Technology in Organic Chemistry and Economics and is inventor on several patents and publications in the field of nucleic acid synthesis and related fields.